search
Back to results

Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management

Primary Purpose

Sickle Cell Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pinpoint App
Sponsored by
Klein Buendel, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Sickle Cell Disease focused on measuring Sickle Cell Disease, Adolescence, Pain Assessment, Tablet Application, Pain, mHealth

Eligibility Criteria

13 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Phone Interview, Focus Group, and Usability Inclusion Criteria:

  • Be 13-17 years of age
  • Be diagnosed with Sickle Cell Disease
  • Able to read and speak English
  • Able to assent to participate

Phone Interview, Focus Group, and Usability Exclusion Criteria:

  • Not 13-17 years of age
  • Not diagnosed with Sickle Cell Disease
  • Unable to read and speak English
  • Unable to assent to participate

Healthcare Provider Interview Inclusion Criteria:

  • Be a healthcare provider to teens with sickle cell disease
  • Be 18 years of age or older
  • Able to read and speak English
  • Able to consent to participate

Healthcare Provider Interview Exclusion Criteria:

  • Not a healthcare provider to teens with sickle cell disease
  • Not 18 years of age or older
  • Unable to read and speak English
  • Unable to consent to participate

Sites / Locations

  • Klein Buendel, Inc.
  • Hilton Publishing Company

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pinpoint App

Arm Description

Tablet application.

Outcomes

Primary Outcome Measures

System Usability Questionnaire
Ten likert-type questions assessing user-friendliness of technology. Each question has five answer options that range from "Strongly Agree" to "Strongly Disagree". Scores range from 0-100. A score of 68 or above is considered above average. All scores averaged.

Secondary Outcome Measures

Full Information

First Posted
September 20, 2017
Last Updated
January 14, 2019
Sponsor
Klein Buendel, Inc.
Collaborators
Hilton Publishing Company, National Institute on Minority Health and Health Disparities (NIMHD)
search

1. Study Identification

Unique Protocol Identification Number
NCT03291613
Brief Title
Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management
Official Title
PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Management
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
January 15, 2017 (Actual)
Primary Completion Date
September 30, 2017 (Actual)
Study Completion Date
September 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Klein Buendel, Inc.
Collaborators
Hilton Publishing Company, National Institute on Minority Health and Health Disparities (NIMHD)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet assessments to identify type, intensity, frequency, and phase of pain among SCD adolescents is lacking. Research shows that interactive gaming technology can enhance adolescents' learning, and can be especially effective in delivering health-related messages and tools to improve their self-care. Pinpoint is an interactive gaming tablet app that will be developed with the significant input of clinical experts to assist SCD teens with better identification and self-report of their pain.
Detailed Description
Sickle cell disease (SCD) is the most common inherited blood disorder in the U.S. and disproportionately affects African Americans and Hispanics. Approximately, 1,000 U.S. children are born with SCD annually. SCD results from abnormal hemoglobin and causes red blood cells (RBCs) to become misshaped ("sickle-shaped"). Sickled cells can block the flow of blood in small arteries causing tissue and organ damage and other life-threatening comorbidities. SCD complications can be serious and have a significant impact upon well-being and quality of life. Pain is the hallmark symptom associated with SCD, and is the most common clinical problem seen in children and the number one cause of SCD-related hospital admissions. If left untreated, these painful episodes can result in morbidity and mortality. Accurate assessment of pain specifiers (type, frequency, and intensity of pain) can help with ameliorating pain quickly and effectively. Despite children being accurate self-reporters of their pain, strategies which are effective and engaging to assist with pain identification are lacking. Reducing barriers to collection and promoting the value of accurate SCD pain assessment is a need in pediatric medicine. Pinpoint will be an innovative interactive assessment tool that engages patients while allowing physicians to collect important health data. This project will test the feasibility of applying gamification principles to develop a tablet application ("app") for 13-17 year olds with SCD. Specifically, this Phase I SBIR project will (1) develop a Pain Assessment Tool (PAT) to describe and categorize specific types of pain experienced by adolescents with SCD; and (2) create an app ("Pinpoint"), that will translate the PAT into gamified technology. The goal of Pinpoint is to engage adolescent patients and improve pain specification by developing a game-based pain assessment tool delivered via a tablet app to engage adolescent SCD patients, improve their pain specification self-report, and improve pain management by clinicians. The PAT will be developed using expert guidance from preeminent SCD clinicians. User-centered Design theory will be applied in the development of the app and will be guided by iterative cognitive interviews and focus groups with members of the target population, SCD teens. The project specific aims are to (1) develop the PAT using guidance from an Expert Advisory Board (EAB) of SCD clinicians; (2) conduct a series of cognitive interviews with adolescent SCD patients to guide and refine PAT development; (3) conduct iterative focus groups with adolescent SCD patients to guide and refine user interface design of the Pinpoint app; (4) program a functional Pinpoint prototype; and (5) conduct usability testing of the prototype with 13-17 year old SCD patients to assess functionality, navigation, and satisfaction. This project is innovative and timely. Pinpoint will be the first tablet app to identify and translate specific pain types for SCD into a gamified app using applied gamification principles.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease
Keywords
Sickle Cell Disease, Adolescence, Pain Assessment, Tablet Application, Pain, mHealth

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pinpoint App
Arm Type
Experimental
Arm Description
Tablet application.
Intervention Type
Other
Intervention Name(s)
Pinpoint App
Intervention Description
Tablet app with pain assessment and communication education, and pain assessment tool.
Primary Outcome Measure Information:
Title
System Usability Questionnaire
Description
Ten likert-type questions assessing user-friendliness of technology. Each question has five answer options that range from "Strongly Agree" to "Strongly Disagree". Scores range from 0-100. A score of 68 or above is considered above average. All scores averaged.
Time Frame
After 1-hour usability session

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Phone Interview, Focus Group, and Usability Inclusion Criteria: Be 13-17 years of age Be diagnosed with Sickle Cell Disease Able to read and speak English Able to assent to participate Phone Interview, Focus Group, and Usability Exclusion Criteria: Not 13-17 years of age Not diagnosed with Sickle Cell Disease Unable to read and speak English Unable to assent to participate Healthcare Provider Interview Inclusion Criteria: Be a healthcare provider to teens with sickle cell disease Be 18 years of age or older Able to read and speak English Able to consent to participate Healthcare Provider Interview Exclusion Criteria: Not a healthcare provider to teens with sickle cell disease Not 18 years of age or older Unable to read and speak English Unable to consent to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valerie Myers, PhD
Organizational Affiliation
Klein Buendel, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Klein Buendel, Inc.
City
Golden
State/Province
Colorado
ZIP/Postal Code
80401
Country
United States
Facility Name
Hilton Publishing Company
City
Munster
State/Province
Indiana
ZIP/Postal Code
463213963
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
18458271
Citation
Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008 Jun 17;148(12):932-8. doi: 10.7326/0003-4819-148-12-200806170-00220. Epub 2008 May 5. No abstract available.
Results Reference
background
Citation
Cope A, Darbyshire PJ. Sickle cell disease, update on management. Paediatrics and Child Health. 2013;23(11):480-485.
Results Reference
background
Citation
Mukerji I. About sickle cell disease.Sicklecellinfo.net Web site. Available at: http://www.sicklecellinfo.net/index.htm. Published 2004. Updated March 5, 2004. Accessed March 5, 2015.
Results Reference
background
PubMed Identifier
25125865
Citation
Bhagat VM, Baviskar SR, Mudey AB, Goyal RC. Poor health related quality of life among patients of sickle cell disease. Indian J Palliat Care. 2014 May;20(2):107-11. doi: 10.4103/0973-1075.132622.
Results Reference
background
PubMed Identifier
15683091
Citation
Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP. Sickle cell disease; a general overview. Neth J Med. 2004 Nov;62(10):364-74.
Results Reference
background
PubMed Identifier
12662119
Citation
Stinson J, Naser B. Pain management in children with sickle cell disease. Paediatr Drugs. 2003;5(4):229-41. doi: 10.2165/00128072-200305040-00003.
Results Reference
background
PubMed Identifier
24378816
Citation
Ameringer S, Elswick RK Jr, Smith W. Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health-related quality of life. J Pediatr Oncol Nurs. 2014 Jan-Feb;31(1):6-17. doi: 10.1177/1043454213514632. Epub 2013 Dec 30.
Results Reference
background
PubMed Identifier
14622732
Citation
Dampier C, Ely B, Brodecki D, O'Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 2002 Dec;3(6):461-70. doi: 10.1054/jpai.2002.128064.
Results Reference
background
PubMed Identifier
25503599
Citation
Schatz J, Schlenz AM, McClellan CB, Puffer ES, Hardy S, Pfeiffer M, Roberts CW. Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones. Clin J Pain. 2015 Jun;31(6):536-47. doi: 10.1097/AJP.0000000000000183.
Results Reference
background
PubMed Identifier
20658620
Citation
Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W; Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC). Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer. 2010 Sep;55(3):485-94. doi: 10.1002/pbc.22497.
Results Reference
background
PubMed Identifier
16083431
Citation
Crandall M, Savedra M. Multidimensional assessment using the adolescent pediatric pain tool: a case report. J Spec Pediatr Nurs. 2005 Jul-Sep;10(3):115-23. doi: 10.1111/j.1744-6155.2005.00023.x.
Results Reference
background
PubMed Identifier
11844631
Citation
Franck LS, Treadwell M, Jacob E, Vichinsky E. Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. J Pain Symptom Manage. 2002 Feb;23(2):114-20. doi: 10.1016/s0885-3924(01)00407-9.
Results Reference
background
PubMed Identifier
25502156
Citation
Lopez G, Liles DK, Knupp CL. Edmonton Symptom Assessment System for outpatient symptom monitoring of sickle cell disease. South Med J. 2014 Dec;107(12):768-72. doi: 10.14423/SMJ.0000000000000209.
Results Reference
background
PubMed Identifier
16042695
Citation
Panepinto JA, O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005 Aug;130(3):437-44. doi: 10.1111/j.1365-2141.2005.05622.x.
Results Reference
background

Learn more about this trial

Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management

We'll reach out to this number within 24 hrs